Ok, now I would LOVE to see the same trial using the new parp inhibitor saruparib , which is considered waaaaay less toxic and more targeted compared to the others, but…
The TALAPRO-2 trial confirmed that talazoparib + enzalutamide significantly improves overall survival (OS) in HRR-deficient mCRPC, with BRCA1/2-mutated patients seeing the greatest benefit. Their median OS was not reached, compared to 28.5 months with enzalutamide alone. For non-BRCA HRR mutations, the 10-month OS improvement (42.4 vs. 32.6 months) showed a positive trend but was not statistically significant yet (a bigger sample is probably needed). The findings reinforce HRR testing as critical for treatment selection, solidifying PARP inhibition as a key strategy in BRCA1/2-driven mCRPC. The trend looks positive also for the other HRR mutations but further research is needed to confirm it.